[Bone effects of bisphosphonates and denosumab treatments in breast or prostate cancer].
Two types of bone diseases can be observed in patients with breast or prostate cancer: fragility fractures related to osteoporosis, and skeletal related events (SRE) complicating bone metastases. Aromatase inhibitors, ovarian function suppression and tamoxifen use in pre-menopausal women, and androgen deprivation therapy, induce a decrease of bone mineral density and an increase of the incidence of fractures, which can be prevented by inhibitors of bone resorption at low doses. In addition, adjuvant bisphosphonates may be associated with benefits on disease free survival, especially regarding bone recurrences, in postmenopausal women with non-metastatic breast cancer. In the presence of bone metastases, inhibitors of bone resorption at higher doses and frequencies prevent SRE.